Danish drugmaker Bavarian Nordic's first-quarter 2007 revenues totaled 28.8 million kroner ($5.2 million) versus 35.8 million kroner in the like, year-ago period, while the firm's loss before tax narrowed to 51.7 million kroner from 60.9 million kroner.
The company maintained its guidance for the full year, with revenues of around 130.0 million kroner and a loss before tax of 350.0 million kroner, as the US Government notified the firm of its intent to acquire 20 million doses of Imvamune smallpox vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze